Journal article
Television-viewing time and bodily pain in Australian adults with and without type 2 diabetes: 12-year prospective relationships
FQS Dzakpasu, N Owen, A Carver, P Sethi, CJ Brakenridge, A Salim, DM Urquhart, F Cicuttini, DW Dunstan
BMC Public Health | BMC | Published : 2022
Abstract
Background: Bodily pain is a common presentation in several chronic diseases, yet the influence of sedentary behaviour, common in ageing adults, is unclear. Television-viewing (TV) time is a ubiquitous leisure-time sedentary behaviour, with a potential contribution to the development of bodily pain. We examined bodily pain trajectories and the longitudinal relationships of TV time with the bodily pain severity; and further, the potential moderation of the relationships by type 2 diabetes (T2D) status. Method: Data were from 4099 participants (aged 35 to 65 years at baseline) in the Australian Diabetes, Obesity and Lifestyle Study (AusDiab), who took part in the follow-ups at 5 years, 12 year..
View full abstractGrants
Awarded by National Health and Medical Research Council
Funding Acknowledgements
The AusDiab which was co-coordinated by the Baker Heart and Diabetes Institute was sponsored by National Health and Medical Research Council (NHMRC grants 233200 and 1007544); Australian Government Department of Health and Ageing, Abbott Australasia Pty Ltd., Alphapharm Pty Ltd.; Amgen Australia; AstraZeneca, Bristol-Myers Squibb; City Health Centre-Diabetes Service-Canberra; Department of Health and Community Services - Northern Territory; Department of Health and Human Services - Tasmania; Department of Health - New South Wales; Department of Health - Western Australia; Department of Health - South Australia; Department of Human Services - Victoria; Diabetes Australia; Diabetes Australia Northern Territory; Eli Lilly Australia; Estate of the Late Edward Wilson; GlaxoSmithKline; Jack Brockhoff Foundation, Janssen-Cilag; Kidney Health Australia; Marian & FH Flack Trust; Menzies Research Institute; Merck Sharp & Dohme; Novartis Pharmaceuticals; Novo Nordisk Pharmaceuticals; Pfizer Pty Ltd.; Pratt Foundation; Queensland Health; Roche Diagnostics Australia; Royal Prince Alfred Hospital - Sydney, Sanofi Aventis; Sanofi-synthelabo; and the Victorian Government's OIS Program. Dzakpasu and Brakenridge were supported by the Australian Government Research Training Program Scholarship. Owen was supported by the National Health and Medical Research Council (NHMRC) of Australia through a Senior Principal Research Fellowships (#1003960) and by the Victorian Government's Operational Infrastructure Support Program. Dunstan was supported by an NHMRC Senior Research Fellowship (1078360) and the Victorian Government's Operational Infrastructure Support Program. Urquhart was supported by an NHMRC Career Development Fellowship (Clinical Level 2; 1142809). Cicuttini was supported by an NHMRC Investigator Grant (APP1194829). None of the funders had a role in the design, data analysis, or interpretation of the results presented in this manuscript.